p16 Inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus
Authors:
- Maria–Chiara OsterheldMOMaria–Chiara Osterheld
- Charlotte FontollietCFCharlotte Fontolliet
- Fred T. BosmanFBFred T. Bosman
- Jean BenhattarJBJean Benhattar
- 1 April 2002
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 122 (4) , 1113-1121
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Clonal Expansion and Loss of Heterozygosity at Chromosomes 9p and 17p in Premalignant Esophageal (Barrett's) TissueJNCI: Journal of the National Cancer Institute, 1999
- Evolution of neoplastic cell lineages in Barrett oesophagusNature Genetics, 1999
- Hypermethylation of the CDKN2/p16 promoter during neoplastic progression in Barrett's esophagusGastroenterology, 1998
- Cancer Cell CyclesScience, 1996
- Frequency of homozygous deletion at p16/CDKN2 in primary human tumoursNature Genetics, 1995
- Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16Nature, 1995
- Prevalence of metaplasia at the gastro-oesophageal junctionThe Lancet, 1994
- A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor TypesScience, 1994
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993
- Barrett's EsophagusGastroenterology Clinics of North America, 1991